Tirapazamine has been explored in clinical trials for a variety of cancer types, including head and neck cancer, non-small cell lung cancer (NSCLC), cervical cancer, and others. The drug's ability to target hypoxic tumor cells makes it a promising candidate for tumors that are difficult to treat with standard methods.
